|
|
||||||||
Departments of Paediatric Oncology, Physics and Pathology, and Section of Medicine, The Royal Marsden Hospital, Sutton
Institute of Cancer Research, Sutton
Department of Surgery, Queen Mary's Hospital for Children, Carshalton, Surrey, UK
Correspondence: For reprints contact: Judy Moyes, MD, Dept. of Paediatrics, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
ABSTRACT
Six children with neuroblastoma and one with ganglioneuroma received [125I] metaiodobenzylguanidine (MIBG) before major surgery. Uptake of [125I]MIBG in the excised tissues was measured by scintillation counting, and the material was submitted for histopathology. The ranges of uptake of [125I]MIBG, expressed as percent of the injected dose per gram of tissue, were as follows: for neuroblastoma 0.00130.071, for ganglioneuroma 0.00170.0028, and for non-neoplastic control tissues 0.00020.011. The quantitative uptake of [125I]MIBG by neuroblastoma varied between different patients and between different parts of individual tumors. The more undifferentiated tumors took up more [125I]MIBG and may be more likely to respond to targeted radiotherapy with MIBG.
This article has been cited by other articles:
![]() |
S. MELLER Targeted radiotherapy for neuroblastoma Arch. Dis. Child., November 1, 1997; 77(5): 389 - 392. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |